Dr. Kami J. Maddocks, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Sanford School of Medicine of University of South Dakota (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 202
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Sanford School of Medicine of University of South Dakota
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35.091776
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 202
- Services billed
- 499
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 111 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 102 | 91 |
| Established patient office or other outpatient visit, 20-29 minutes | 68 | 66 |
| Established patient office or other outpatient visit, 40-54 minutes | 67 | 50 |
| Hospital discharge day management, more than 30 minutes | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 58 |
| Calquence (acalabrutinib maleate) | 46 |
| Imbruvica (ibrutinib) | 17 |
| Venclexta (venetoclax) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 43 payments worth $48,201 in total to this clinician.
| Adc Therapeutics America, Inc. | $13,197 |
|---|---|
| Incyte Corporation | $10,970 |
| AbbVie Inc. | $9,615 |
| Genentech USA, Inc. | $7,971 |
| E.r. Squibb & Sons, L.l.c. | $2,388 |
| AstraZeneca Pharmaceuticals LP | $1,640 |
| Beone Medicines USA, Inc. | $1,600 |
| AstraZeneca UK Limited | $820 |
| Consulting Fee | $31,279 |
|---|---|
| Honoraria | $11,900 |
| Travel and Lodging | $3,836 |
| Food and Beverage | $1,186 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Adc Therapeutics America, Inc. Sep 30, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $11,900 |
| Incyte Corporation Apr 16, 2025 | Consulting Fee | $7,193 |
| AbbVie Inc. Apr 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| AbbVie Inc. Dec 22, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| Genentech USA, Inc. Jul 28, 2025 | Consulting Fee Polivy; Columvi; Lunsumio · BioOncology | $2,870 |
| Genentech USA, Inc. Apr 30, 2025 | Consulting Fee Columvi · BioOncology | $2,460 |
| Genentech USA, Inc. Dec 4, 2025 | Consulting Fee Polivy · BioOncology | $2,460 |
| E.r. Squibb & Sons, L.l.c. Mar 5, 2025 | Consulting Fee | $2,388 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,055 |
| AbbVie Inc. Apr 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,994 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 22, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,055 |
| Genentech USA, Inc. Dec 4, 2025 | Consulting Fee Polivy · BioOncology | $2,460 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging travel to Orlando, FL | $37.02 |
| Beone Medicines USA, Inc. Nov 21, 2025 | Consulting Fee BRUKINSA · Oncology | $1,600 |
| Adc Therapeutics America, Inc. Oct 10, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA | $132 |
| Adc Therapeutics America, Inc. Sep 30, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $11,900 |
| Adc Therapeutics America, Inc. Sep 19, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA · in-kind | $573 |
| Adc Therapeutics America, Inc. Sep 19, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA · in-kind | $371 |
| Genentech USA, Inc. Jul 28, 2025 | Consulting Fee Polivy; Columvi; Lunsumio · BioOncology | $2,870 |
| AstraZeneca UK Limited Jul 21, 2025 | Consulting Fee CALQUENCE · Oncology | $820 |
| Genentech USA, Inc. Apr 30, 2025 | Consulting Fee Columvi · BioOncology | $2,460 |
| Incyte Corporation Apr 16, 2025 | Consulting Fee | $7,193 |
| AbbVie Inc. Apr 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| AbbVie Inc. Apr 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,994 |
| AbbVie Inc. Mar 15, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $851 |
| AbbVie Inc. Mar 15, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $268 |
| AbbVie Inc. Mar 15, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $112 |
| AbbVie Inc. Mar 14, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $112 |
| E.r. Squibb & Sons, L.l.c. Mar 5, 2025 | Consulting Fee | $2,388 |
| Incyte Corporation Feb 28, 2025 | Travel and Lodging travel to Austin, TX | $598 |
| Incyte Corporation Feb 28, 2025 | Travel and Lodging travel to Austin, TX | $208 |
| Incyte Corporation Feb 27, 2025 | Travel and Lodging travel to Austin, TX | $355 |
| Incyte Corporation Feb 27, 2025 | Travel and Lodging travel to Austin, TX | $219 |
| AstraZeneca Pharmaceuticals LP Jan 16, 2025 | Consulting Fee CALQUENCE · Oncology | $1,640 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $1,282,129 in research payments for these studies, mostly to the institutions running them.
- PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
AbbVie Inc. · Active, not recruiting · NCT01589302 - Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
AbbVie Inc. · Active, not recruiting · NCT01479842 - A Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma
Acerta Pharma LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.